The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells

Show simple item record

dc.contributor.author Alshangiti, Amnah M.
dc.contributor.author Togher, Katie L.
dc.contributor.author Hegarty, Shane V.
dc.contributor.author Sullivan, Aideen M.
dc.contributor.author O'Keeffe, Gerard W.
dc.date.accessioned 2019-11-19T12:01:52Z
dc.date.available 2019-11-19T12:01:52Z
dc.date.issued 2019-01-30
dc.identifier.citation Alshangiti, A., Togher, K., Hegarty, S.V., Sullivan, A.M. and O'Keeffe, G.W., 2019. The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells. Neuronal Signaling, (NS20180201). DOI:10.1042/NS20180201 en
dc.identifier.volume 3 en
dc.identifier.issued 1 en
dc.identifier.startpage 1 en
dc.identifier.endpage 13 en
dc.identifier.uri http://hdl.handle.net/10468/9073
dc.identifier.doi 10.1042/NS20180201 en
dc.description.abstract Neuroblastoma (NB) is the most common extracranial solid tumor of early childhood; it accounts for approximately 8–10% of all childhood cancers and is the most common cancer in children in the first year of life. Patients in the high-risk group have a poor prognosis, with relapses being common and often refractory to drug treatment in those that survive. Moreover, the drug treatment itself can lead to a range of long-term sequelae. Therefore, there is a critical need to identify new therapeutics for NB. Isoliquiritigenin (ISLQ) is a naturally-occurring, dietary chalcone-type flavonoid with a range of biological effects that depend on the cell type and context. ISLQ has potential as an anticancer agent. Here we show that ISLQ has potent cytotoxic effects on SK-N-BE(2) and IMR-32 human NB cells, which carry amplification of the MYCN gene, the main prognostic marker of poor survival in NB. ISLQ was found to increase cellular reactive oxygen species (ROS). The cytotoxic effect of ISLQ was blocked by small molecule inhibitors of oxidative stress-induced cell death, and by the antioxidant N-acetyl-l-cysteine (NAC). Combined treatment of either SK-N-B-E(2) or IMR-32 cells with ISLQ and the anticancer agent cisplatin resulted in loss of cell viability that was greater than that induced by cisplatin alone. This study provides proof-of-principle that ISLQ is a potent cytotoxin for MYCN-amplified human NB cells. This is an important first step in rationalizing the further study of ISLQ as a potential adjunct therapy for high-risk NB. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Portland Press en
dc.relation.uri http://www.neuronalsignaling.org/content/3/1/NS20180201
dc.rights © 2019 The Author(s) en
dc.rights.uri https://creativecommons.org/licenses/by/4.0/ en
dc.subject Neuroblastoma (NB) en
dc.subject Early childhood en
dc.subject Childhood cancer en
dc.subject Therapeutics en
dc.title The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Gerard O'Keeffe, Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.okeeffe@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Government of Saudi Arabia en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Neuronal Signaling en
dc.internal.IRISemailaddress g.okeeffe@ucc.ie en
dc.identifier.articleid NS20180201 en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Career Development Award/15/CDA/3498/IE/Development of GDF5 neurotrophic factor therapy for Parkinson_s disease./ en
dc.identifier.eissn 2059-6553


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 The Author(s) Except where otherwise noted, this item's license is described as © 2019 The Author(s)
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement